Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novavax

COVID-19 booster uptake remains low, despite growing evidence they’re as good as older shots

DENVER — More than two months into the campaign to get people to take updated COVID-19 boosters, only about 8% of people who are eligible have received the shot, though about 23% of those 65 and older have, according to Centers for Disease Control and Prevention estimates.

The Denver Post

Biotech Firestorm Takes Down Novavax Despite Quadrupled Sales

Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.

Investors Business Daily

Novavax says Omicron shot shows strong immune response as second booster

Vaccine maker Novavax Inc said on Tuesday its COVID-19 shot retooled against the Omicron BA.1 variant showed a strong immune response as the fourth dose and met the main goal of strain change in a late-stage study.

Reuters

From analysis to the latest developments in health,
read the most diverse news in one place.

US clears Novavax COVID booster dose

The Food and Drug Administration has authorized a booster dose of the COVID-19 vaccine made by Novavax

The Independent UK

Why Novavax's Uphill Battle Continues Despite Winning U.S. Booster Authorization

Novavax won Food and Drug Administration for its Covid booster on Wednesday, but NVAX stock dipped slightly in response.

Investors Business Daily

What vaccine can you get, based on your age? These are the recommended COVID-19 vaccines for each age group

More than 14.2 million Australians over the age of 16 have now received three or more doses. So which are the best vaccines for each age group?

ABC News

Pharma Giants Moderna And Novavax Trend Lower In This Pattern: What's Going On?

Moderna Inc. (NASDAQ: MRNA) and Novavax Inc. (NASDAQ: NVAX) were trading down over 2% and 4%, respectively in the premarket Friday despite both stocks showing signs a bounce could be in the cards.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Here Are Novavax's U.S. Vaccination Numbers — And They're Bleak

Novavax stock is trading at a two-year low amid slowly ramping use of its Covid vaccine, dubbed Nuvaxovid, in the U.S.

Investors Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2022

Upgrades

Benzinga

Novavax Stock Slides As JPMorgan Slashes Price Target, Lowers Rating

JPMorgan analyst Eric Joseph slashed his price target on Novavax by more than $100, to $27 per share.

The Street

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Incyte’s (NASDAQ:INCY) Pemazyre (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with FGFR1 rearrangement. Incyte shares traded in a range of $71.38 to $72.98 on day volume of 1.25…

Benzinga

The Covid Gambit: Pfizer, Moderna Struggle To Get The Jump On Covid

Companies are working to develop updated Covid boosters. Will they be too late to make a difference for the vaccine stocks — and society?

Investors Business Daily

Novavax Covid vaccine approved for 12 to 17 year olds in Britain

Health authorities say the vaccine is safe and effective in this age group

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Covid Stocks Pfizer, Moderna, Novavax Face Their Next Challenge, And It's Worth Billions

The Biden administration is planning to stop paying for Covid vaccines and treatments, a move that could buoy some Covid stocks.

Investors Business Daily

Missed BBBY? 10 'Meme Stocks' Are Next Gold Mines, Analysts Say

Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. Bluebird shares traded in a range of $6.13 to $8.18 on a day…

Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary

Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy candidate for solid tumor cancers, were published today in Nature Medicine. The initial results from the study are expected during second half of 2023. Gritstone shares traded in a range of $3.96 to $4.24…

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Recap Of Friday's Biotech Catalysts - End Of the Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD). The study met two co-primary objectives, associated with immunogenicity responses. Pfizer shares traded in a range of $48.55 to…

Investors Business Daily

Stock Market Loses Ground For Second Day; Micron Warns; Coinbase Set To Report

Stock market indexes traded lower in the first hour of Tuesday's session, with chips and big tech taking the brunt of selling pressure. Energy stocks, led by natural gas plays, rose after Russian oil flows through central Europe were halted. The Dow Jones Industrial Average is trading lower by 0.2%…

Investors Business Daily

Dow Jones Falls As Inflation Report Looms; Covid Vaccine Maker Crashes On Earnings

The Dow Jones Industrial Average fell Tuesday ahead of Wednesday's key inflation report. Vaccine maker Novavax crashed on earnings results.

The Street

Novavax Stock Plummets After Slashing 2022 Vaccine Sales Forecast

"I believe we were late to the market and US vaccination was driven by what was available and shown to work," said Novavax CEO Stanley Erck.

The Street

Stocks Edge Higher, Tesla, Boeing, Novavax And Take-Two Interactive in Focus - Five Things To Know

Stock futures edge higher with inflation data in sight; Tesla nudges higher despite China sales slump; Boeing moves higher on 787 Dreamliner delivery report; Novavax plummets after slashing vaccine sales forecasts and Take-Two Interactive slides on muted video gaming outlook

The Hindu

Morning Digest | India finishes 4th as Commonwealth Games closes; BJP says it will stand by ally JD(U), and more

A select list of stories to read before you start your day

Investors Business Daily

Novavax Stock Plummets As 'Market Dynamics' Crush Its 2022 Sales Outlook

Novavax widely missed second-quarter forecasts Tuesday, leading the Covid vaccine maker to slash its guidance and NVAX stock to crash.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Bharatiya Janata Party

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.